VALEANT PHARMACEUTICALS INTL I (VRX) Stock Price & Overview
NYSE:VRX • CA91911K1021
Current stock price
The current stock price of VRX is 23.4 null. Today VRX is down by -3.43%. In the past month the price decreased by -12.69%. In the past year, price increased by 35.73%.
VRX Key Statistics
- Market Cap
- 8.16B
- P/E
- 5.91
- Fwd P/E
- 6.74
- EPS (TTM)
- 3.96
- Dividend Yield
- N/A
VRX Stock Performance
VRX Stock Chart
VRX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to VRX. When comparing the yearly performance of all stocks, VRX is one of the better performing stocks in the market, outperforming 90.59% of all stocks.
VRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VRX. While VRX is still in line with the averages on profitability rating, there are concerns on its financial health.
VRX Earnings
VRX Forecast & Estimates
VRX Financial Highlights
Over the last trailing twelve months VRX reported a non-GAAP Earnings per Share(EPS) of 3.96. The EPS decreased by -29.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -10.65% | ||
| ROA | -2.56% | ||
| ROE | -20.27% | ||
| Debt/Equity | 5.59 |
VRX Ownership
About VRX
Company Profile
Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant's development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.
Company Info
VALEANT PHARMACEUTICALS INTL I
2150 ST. ELZEAR BLVD. WEST
LAVAL A8 H7L 4A8
CEO: Joseph C. Papa
Phone: 514-744-6792
VALEANT PHARMACEUTICALS INTL I / VRX FAQ
What does VRX do?
Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant's development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.
Can you provide the latest stock price for VALEANT PHARMACEUTICALS INTL I?
The current stock price of VRX is 23.4 null. The price decreased by -3.43% in the last trading session.
What is the dividend status of VALEANT PHARMACEUTICALS INTL I?
VRX does not pay a dividend.
What is the ChartMill rating of VALEANT PHARMACEUTICALS INTL I stock?
VRX has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of VALEANT PHARMACEUTICALS INTL I (VRX) based on its PE ratio?
The PE ratio for VALEANT PHARMACEUTICALS INTL I (VRX) is 5.91. This is based on the reported non-GAAP earnings per share of 3.96 and the current share price of 23.4 null.
Should I buy VRX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on VRX.